Shots:

• The NMPA has approved Entyvio to treat patients with moderately to severely active UC & CD having inadequate response to- lost response to- or were intolerant to conventional therapies or TNFα inhibitors
• In 2018- NMPA has included the therapy in the first batch list of ‘urgently needed’ overseas medicines for accelerated approval
• Entyvio (IV) is a gut-selective mAb- designed to specifically antagonize the α4β7 integrin to intestinal (MAdCAM-1) but not VCAM-1 and has received marketing authorization in 60+ countries including the US and EU

Click here to­ read full press release/ article 

 Ref: Takeda | Image:Takeda